← All Marizyme, INC filings

Marizyme, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink
MRZM
Marizyme, INC
10-K/A: Marizyme Restates 2023 Financials, Cites Material Weakness in Internal Controls
Marizyme, Inc. restated its 2023 financial statements due to errors in convertible note accounting and identified a material weakness in its internal controls over financial reporting.
OTC.Pink
MRZM
Marizyme, INC
10-K: Marizyme, Inc. 10-K Filing: Details on Securities, Financials, and Future Strategy
Marizyme, Inc.'s 10-K filing provides a comprehensive overview of the company's securities, financial performance, and strategic direction, highlighting its focus on DuraGraft commercialization and other medical technologies.